Signals, Powered By EquityPandit
Cadila Healthcare has received an Establishment Inspection Report (EIR) from the US health regulator for its manufacturing plant in Ahmedabad.
Cadila Healthcare Ltd has said in a BSE filing that “The company’s Oral Solid Dosage drug manufacturing plant located at SEZ, Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA following the inspection carried out in January 2016.”
The company has said further that “The receipt of EIR indicates the successful closure of the inspection points raised. It may be mentioned that this plant is a separate manufacturing unit and does not form a part of the Moraiya formulations manufacturing facility.”
